Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immix Biopharma, Inc. - Common Stock (NQ: IMMX )

2.420 +0.020 (+0.83%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 51,520
Open 2.400
Bid (Size) 2.300 (3)
Ask (Size) 2.500 (2)
Prev. Close 2.400
Today's Range 2.350 - 2.473
52wk Range 0.6800 - 5.370
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Immix Biopharma Doses Additional Patients in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial
From Immix Biopharma, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga

Performance

YTD
+9.01%
+9.01%
1 Month
+9.01%
+9.01%
3 Month
+142.00%
+142.00%
6 Month
+0.41%
+0.41%
1 Year
-40.39%
-40.39%

More News

Read More
Immix Biopharma Subsidiary Nexcella, Inc. Announces Additional Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in Relapsed/Refractory AL Amyloidosis Patients, Duration of Response Not Yet Reached
From Immix Biopharma, Inc.
Via Globe NewsWire
Nexcella, Inc., a subsidiary of Immix Biopharma, announces poster presentation at the European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting
From Immix Biopharma, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Immix Biopharma Announces 16th Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial
From Immix Biopharma, Inc.
Via Globe NewsWire
ImmixBio Ships Tislelizumab for Patient Dosing in its Combination Clinical Trial with IMX-110 in Advanced Solid Tumors
From Immix Biopharma, Inc.
Via Globe NewsWire
Dow Drops Over 300 Points After Fed Raises Key Overnight Interest Rate By 50 bps
Via Benzinga
Dow Surges Over 100 Points; Charter Communications Shares Slide
Via Benzinga
Why Immix Biopharma Shares Are Surging Today?
Via Benzinga
Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 50 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Immix Biopharma in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amyloidosis (100% Complete Responses)
From Immix Biopharma, Inc.
Via Globe NewsWire
Immix Biopharma Announces Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial
From Immix Biopharma, Inc.
Via Globe NewsWire
ImmixBio Releases and Ships Scaled-Up GMP Batches of IMX-110 for Clinical Trial Patient Dosing
From Immix Biopharma, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
121 Stocks That Hit Their 52-Week Low
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.